Lungs News and Research

RSS

Study identifies mechanism that interrupts normal p53 gene function leading to tumor development

The p53 gene has been a well-documented player in the prevention of tumors. It is considered the most frequently mutated gene in human tumors with more than half harboring p53 mutations (Bennett et al., 1999). These mutations often can be caused by disruption in normal p53 function.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

22 Midwest facilities named Centers of Excellence in accelerated partial breast irradiation

Twenty-two facilities in the Midwest have been named Centers of Excellence in accelerated partial breast irradiation (APBI) for their use of the SAVI® applicator, an advanced therapy for breast cancer as part of breast conservation therapy. The SAVI applicator can provide important advantages for women with early-stage breast cancer.

10 Jun 2010

Misinterpretation of genetic information may undermine efforts to promote behavioral changes for disease prevention

Does knowing that genes are partly responsible for your health condition mean you are less likely to be motivated to find out about the benefits of behavioral changes? According to Dr. Suzanne O'Neill from the National Human Genome Research Institute/National Institutes of Health, and her colleagues, people on the whole are still interested in how health habits affect disease risk.

10 Jun 2010

Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer

Adding a second agent may make a new, experimental anti-cancer drug effective against a wide range of cancers, researchers at the University of Illinois at Chicago College of Medicine have found.

10 Jun 2010

People who smoke immediately after waking may be at risk for lung cancer: Study

People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smoke, regardless of the number of cigarettes smoked.

10 Jun 2010

Online self-management tool improves asthma patients' ability to reduce their symptoms

An online self-management tool for people with asthma has been shown to significantly improve their ability to reduce their symptoms. Researchers writing in BioMed Central's open access journal Respiratory Research tested the system in 200 adults with asthma, finding significant effects in those whose asthma was either partly controlled or uncontrolled at the beginning of the trial.

10 Jun 2010

Veracyte announces completion of Series B round

Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company's first product launch later this year. The South San Francisco biotechnology company is committed to pioneering molecular cytology diagnostics to improve patient care and lower health care costs. This round was led by Domain Associates with significant participation from Veracyte's founding investors including Kleiner Perkins Caufield & Byers (KPCB), TPG Biotech (TPG), and Versant Ventures.

10 Jun 2010

PulmoBind product candidate has potential for early diagnosis of PH in pediatric population

Pulmo BioTech Inc. has announced that early indications are that its PulmoBind product candidate has the potential for early diagnosis of Pulmonary Hypertension in the pediatric population. PH is a potentially life threatening and crippling disease; it is also very hard to diagnose.

9 Jun 2010

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

The Cancer Research Institute, a nonprofit organization dedicated to the development of immune system-based treatments for cancer, announced today its celebration of a significant new breakthrough in the treatment of melanoma, the deadliest form of skin cancer. The new treatment, a cancer immunotherapy created by Cancer Research Institute Scientific Advisory Council Associate Director James P. Allison, Ph.D., is designed to "take the brakes off the immune system," and is the first treatment ever proven to extend life for patients whose melanomas are unresponsive to existing cancer therapies.

9 Jun 2010

Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced Phase 1 data for its novel heart failure Positron Emission Tomography (PET) imaging agent, LMI 1195, which is in development for the evaluation of patients at risk of heart failure or sudden cardiac death.

9 Jun 2010

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Aerovance Inc. today announced top-line results from its Phase 2b clinical trial that show the inhaled dry powder formulation of Aerovant (pitrakinra inhalation powder) is effective in a pre-defined subset of patients with eosinophilic asthma.

8 Jun 2010

MicroStockProfit.com: ARIA reports net loss of $23.4M for three months ended March 31, 2010

MicroStockProfit.com announces an investment report featuring ARIAD Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

8 Jun 2010

Clarient granted U.K. patent for TLE3 biomarker

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company's TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy.

8 Jun 2010

Give a Scan: First open access website for CT scans and clinical data

Lung Cancer Alliance, the only national non-profit dedicated to providing support and advocacy for those living with or at risk for lung cancer, announced today the launching of the first open access website for CT scans and clinical data donated by patients, called Give a Scan, that will increase and accelerate research for lung cancer screening, diagnosis, treatment and drug development.

8 Jun 2010

Gene variant linked to ability of Tibetans to cope with low-oxygen conditions identified

A new study pinpoints the genetic changes that enable Tibetans to thrive at altitudes where others get sick.

8 Jun 2010

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.

8 Jun 2010

Chemotherapy drug sunitinib promising for HIV-positive cancer patients

Preliminary findings from a unique study with sunitinib suggest that it might be possible to tweak the dosage of chemotherapy drugs used to treat HIV-positive cancer patients to achieve therapeutic benefit. Given the type of drug cocktail patients use to treat their HIV, much more or considerably less chemotherapy may be warranted, say the researchers, part of the NCI-supported AIDS Malignancy Consortium (AMC). The trial design is being presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

Polaris' ADI-PEG 20 novel anticancer drug inhibits growth of metastatic melanoma cells: Study

Physicians attending the annual meeting of the American Society of Clinical Oncology (ASCO) presented evidence that pegylated arginine deiminase (ADI-PEG 20), a novel anticancer drug that targets ASS(-) tumors, and which is being developed and manufactured by Polaris Group, was effective in inhibiting the growth of metastatic melanoma cells.

8 Jun 2010

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.

8 Jun 2010

Lungs News and Research

Study identifies mechanism that interrupts normal p53 gene function leading to tumor development

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

22 Midwest facilities named Centers of Excellence in accelerated partial breast irradiation

Misinterpretation of genetic information may undermine efforts to promote behavioral changes for disease prevention

Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer

People who smoke immediately after waking may be at risk for lung cancer: Study

Online self-management tool improves asthma patients' ability to reduce their symptoms

Veracyte announces completion of Series B round

PulmoBind product candidate has potential for early diagnosis of PH in pediatric population

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

MicroStockProfit.com: ARIA reports net loss of $23.4M for three months ended March 31, 2010

Clarient granted U.K. patent for TLE3 biomarker

Give a Scan: First open access website for CT scans and clinical data

Gene variant linked to ability of Tibetans to cope with low-oxygen conditions identified

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Chemotherapy drug sunitinib promising for HIV-positive cancer patients

Polaris' ADI-PEG 20 novel anticancer drug inhibits growth of metastatic melanoma cells: Study

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

The ultimate guide to lung research tools and protocols eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News